Polymorphisms in Toll-like receptor genes influence antibody responses to cytomegalovirus glycoprotein B vaccine

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Arav Boger, Ravit ^a   Wojcik, Genevieve L ^b   Duggal, Priya ^b   Ingersoll, Roxann G ^b   Beaty, Terri ^b   Pass, Robert F ^c   Yolken, Robert H ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Cytomegalovirus; glycoprotein B vaccine; single nucleotide polymorphisms; Toll like receptors

Indexed keywords

CYTOMEGALOVIRUS;

CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN B, SIMPLEXVIRUS; I KAPPA B KINASE; IKBKE PROTEIN, HUMAN; INTEGRIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; TOLL LIKE RECEPTOR; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADULT; ALLELE; ARTICLE; BIOSYNTHESIS; CLINICAL TRIAL; COHORT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GENETICS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION;

ADULT; ALLELES; ANTIBODIES, VIRAL; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; I-KAPPA B KINASE; INTEGRINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VACCINATION; VIRAL ENVELOPE PROTEINS;

EID: 84857929332     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-140     Document Type: Review

References (48)

1. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Kenneson A, Cannon MJ, Rev Med Virol 2007 17 253 276 10.1002/rmv.535 17579921 (Pubitemid 47066638)
2. Congenital cytomegalovirus disease-20 years is long enough. Yow MD, Demmler GJ, N Engl J Med 1992 326 702 703 10.1056/NEJM199203053261010 1310526
3. Betaherpesviruses in transplant recipients. Griffiths PD, Clark DA, Emery VC, J Antimicrob Chemother 2000 45 Suppl T3 29 34 10855769 (Pubitemid 30195571)
4. Vaccine prevention of maternal cytomegalovirus infection. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G, N Engl J Med 2009 360 1191 1199 10.1056/NEJMoa0804749 19297572
5. Maternal immunity and prevention of congenital cytomegalovirus infection. Fowler KB, Stagno S, Pass RF, JAMA 2003 289 1008 1011 10.1001/jama.289.8.1008 12597753 (Pubitemid 37432932)
6. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. Schleiss MR, Bourne N, Bernstein DI, J Infect Dis 2003 188 1868 1874 10.1086/379839 14673766 (Pubitemid 38064872)
7. Preconceptual administration of an alphavirus replicon UL83 (pp 65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. Schleiss MR, Lacayo JC, Belkaid Y, McGregor A, Stroup G, Rayner J, Alterson K, Chulay JD, Smith JF, J Infect Dis 2007 195 789 798 10.1086/511982 17299708 (Pubitemid 46363923)
8. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK, Lancet 2011 377 1256 1263 10.1016/S0140-6736(11)60136-0 21481708
9. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW, Nat Immunol 2000 1 398 401 10.1038/80833 11062499
10. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP, Wagner H, Kirschning CJ, Ter MV, Schneider-Schaulies S, J Virol 2002 76 8729 8736 10.1128/JVI.76.17.8729-8736.2002 12163593 (Pubitemid 34864068)
11. Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response. Poland GA, Am J Hum Genet 1998 62 215 220 10.1086/301736 9463343 (Pubitemid 28110761)
12. The genetic basis for variation in antibody response to vaccines. Poland GA, Jacobson RM, Curr Opin Pediatr 1998 10 208 215 10.1097/00008480-199804000- 00017 9608902 (Pubitemid 28256723)
13. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag CM, Vollmar J, Schneider PM, Fimmers R, Lancet 2002 360 991 995 10.1016/S0140-6736(02)11083-X 12383669 (Pubitemid 35284111)
14. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA, Hepatology 2004 39 978 988 10.1002/hep.20142 15057902 (Pubitemid 38428937)
15. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G, J Immunol 1995 154 520 529 7814865
16. Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. Pankratz VS, Vierkant RA, O'Byrne MM, Ovsyannikova IG, Poland GA, BMC Immunol 2010 11 48 10.1186/1471-2172-11-48 20923569
17. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Green NM, Marshak-Rothstein A, Semin Immunol 2011 23 106 112 10.1016/j.smim.2011.01.016 21306913
18. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. Boehme KW, Guerrero M, Compton T, J Immunol 2006 177 7094 7102 17082626 (Pubitemid 44715077)
19. The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection. Yurochko AD, Hwang ES, Rasmussen L, Keay S, Pereira L, Huang ES, J Virol 1997 71 5051 5059 9188570 (Pubitemid 27258175)
20. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR, Clin Infect Dis 2007 44 1315 1320 10.1086/514339 17443468 (Pubitemid 46717293)
21. Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum. Hackett DJ, Zhang C, Stefanescu C, Pass RF, Clin Vaccine Immunol 2010 17 836 839 10.1128/CVI.00422-09 20219875
22. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Soroceanu L, Akhavan A, Cobbs CS, Nature 2008 455 391 395 10.1038/nature07209 18701889
23. Integrin alphavbeta3 is a coreceptor for human cytomegalovirus. Wang X, Huang DY, Huong SM, Huang ES, Nat Med 2005 11 515 521 10.1038/nm1236 15834425 (Pubitemid 40685974)
24. Efficient selection of tagging single-nucleotide polymorphisms in multiple populations. Howie BN, Carlson CS, Rieder MJ, Nickerson DA, Hum Genet 2006 120 58 68 10.1007/s00439-006-0182-5 16680432
25. Principal components analysis corrects for stratification in genome-wide association studies. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D, Nat Genet 2006 38 904 909 10.1038/ng1847 16862161 (Pubitemid 44141658)
26. Herpes simplex virus and toll-like receptors. Finberg RW, Knipe DM, Kurt-Jones EA, Viral Immunol 2005 18 457 465 10.1089/vim.2005.18.457 16212524
27. The role of toll-like receptors in herpes simplex infection in neonates. Kurt-Jones EA, Belko J, Yu C, Newburger PE, Wang J, Chan M, Knipe DM, Finberg RW, J Infect Dis 2005 191 746 748 10.1086/427339 15688290 (Pubitemid 40271064)
28. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL, J Infect Dis 2004 190 1841 1849 10.1086/425079 15499542 (Pubitemid 39487831)
29. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, Mudd S, Shamel L, Sovath S, Goode J, Alexopoulou L, Flavell RA, Beutler B, Proc Natl Acad Sci USA 2004 101 3516 3521 10.1073/pnas.0400525101 14993594 (Pubitemid 38338227)
30. Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. Szomolanyi-Tsuda E, Liang X, Welsh RM, Kurt-Jones EA, Finberg RW, J Virol 2006 80 4286 4291 10.1128/JVI.80.9.4286-4291.2006 16611887
31. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW, J Virol 2003 77 4588 4596 10.1128/JVI.77.8.4588-4596. 2003 12663765 (Pubitemid 36402808)
32. Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B. Simmen KA, Singh J, Luukkonen BG, Lopper M, Bittner A, Miller NE, Jackson MR, Compton T, Fruh K, Proc Natl Acad Sci USA 2001 98 7140 7145 10.1073/pnas.121177598 11390970 (Pubitemid 32567916)
33. Engagement of the cellular receptor for glycoprotein B of human cytomegalovirus activates the interferon-responsive pathway. Boyle KA, Pietropaolo RL, Compton T, Mol Cell Biol 1999 19 3607 3613 10207084 (Pubitemid 29193820)
34. Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection. Askar E, Ramadori G, Mihm S, J Med Virol 2010 82 1859 1868 10.1002/jmv.21893 20872712
35. Toll-like receptor polymorphisms and age-related macular degeneration. Edwards AO, Chen D, Fridley BL, James KM, Wu Y, Abecasis G, Swaroop A, Othman M, Branham K, Iyengar SK, Sivakumaran TA, Klein R, Klein BE, Tosakulwong N, Invest Ophthalmol Vis Sci 2008 49 1652 1659 10.1167/iovs.07-1378 18385087
36. Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. Boehme KW, Singh J, Perry ST, Compton T, J Virol 2004 78 1202 1211 10.1128/JVI.78.3.1202-1211.2004 14722275 (Pubitemid 38095830)
37. Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. DeFilippis VR, Alvarado D, Sali T, Rothenburg S, Fruh K, J Virol 2010 84 585 598 10.1128/JVI.01748-09 19846511
38. Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. Martin HJ, Lee JM, Walls D, Hayward SD, J Virol 2007 81 9748 9758 10.1128/JVI.01122-07 17609264 (Pubitemid 350067679)
39. Human cytomegalovirus differentially controls B cell and T cell responses through effects on plasmacytoid dendritic cells. Varani S, Cederarv M, Feld S, Tammik C, Frascaroli G, Landini MP, Soderberg-Naucler C, J Immunol 2007 179 7767 7776 18025223
40. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G, J Immunol 2002 168 4531 4537 11970999 (Pubitemid 34441357)
41. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ, Cell Immunol 2000 203 55 65 10.1006/cimm.2000.1673 10915562 (Pubitemid 30627030)
42. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, Hartmann G, J Immunol 2005 174 4043 4050 15778362 (Pubitemid 40395980)
43. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Seubert A, Calabro S, Santini L, Galli B, Genovese A, Valentini S, Aprea S, Colaprico A, D'Oro U, Giuliani MM, Pallaoro M, Pizza M, O'Hagan DT, Wack A, Rappuoli R, De GE, Proc Natl Acad Sci USA 2011 108 11169 11174 10.1073/pnas.1107941108 21690334
44. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D, Science 2006 314 1936 1938 10.1126/science.1135299 17185603 (Pubitemid 46026117)
45. Roles of an IkappaB kinase-related pathway in human cytomegalovirus- infected vascular smooth muscle cells: a molecular link in pathogen-induced proatherosclerotic conditions. Gravel SP, Servant MJ, J Biol Chem 2005 280 7477 7486 15619605 (Pubitemid 40349639)
46. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T, Nat Immunol 2003 4 491 496 12692549 (Pubitemid 36592443)
47. Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. Boehme KW, Singh J, Perry ST, Compton T, J Virol 2004 78 1202 1211 10.1128/JVI.78.3.1202-1211.2004 14722275 (Pubitemid 38095830)
48. Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. DeFilippis VR, Alvarado D, Sali T, Rothenburg S, Fruh K, J Virol 2010 84 585 598 10.1128/JVI.01748-09 19846511